ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,821 to 1,840 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Clopidogrel vs Placebo: Myocardial Infarction10 of 2,432

7 of 2,449

0.1 points

-0.2 to 0.5

4,881NCT00991029

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Clopidogrel vs Placebo: Minor Hemorrhage40 of 2,432

13 of 2,449

1.1 points

0.5 to 1.7

4,881NCT00991029

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Clopidogrel vs Placebo: Death From Ischemic Vascular Causes6 of 2,432

4 of 2,449

0.1 points

-0.2 to 0.4

4,881NCT00991029

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Clopidogrel vs Placebo: Hemorrhagic Stroke5 of 2,432

3 of 2,449

0.1 points

-0.2 to 0.4

4,881NCT00991029

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Clopidogrel vs Placebo: Other Symptomatic Intracranial Hemorrhage2 of 2,432

0 of 2,449

0.1 points

-0.1 to 0.3

4,881NCT00991029

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Clopidogrel vs Placebo: Death From Any Cause18 of 2,432

12 of 2,449

0.3 points

-0.2 to 0.7

4,881NCT00991029

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Clopidogrel vs Placebo: Ischemic Stroke112 of 2,432

155 of 2,449

-1.7 points

-3.0 to -0.4

4,881NCT00991029

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Clopidogrel vs Placebo: Ischemic or Hemorrhagic Stroke116 of 2,432

156 of 2,449

-1.6 points

-2.9 to -0.3

4,881NCT00991029

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Clopidogrel vs Placebo: Major Hemorrhage23 of 2,432

10 of 2,449

0.5 points

0.1 to 1.0

4,881NCT00991029

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Clopidogrel vs Placebo: deaths from any cause18 of 2,432

12 of 2,449

0.3 points

-0.2 to 0.7

4,881NCT00991029

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Clopidogrel vs Placebo: Composite of Ischemic Stroke, Myocardial Infarction, Death From Ischemic Vascular Causes, or Major Hemorrhage141 of 2,432

167 of 2,449

-1.0 points

-2.4 to 0.3

4,881NCT00991029

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Clopidogrel vs Placebo: serious adverse events382 of 2,432

382 of 2,449

0.1 points

-1.9 to 2.1

4,881NCT00991029

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership vs Control: Number of Participants With a Postpartum Visit2,079 of 3,261

1,038 of 1,616

-0.5 points

-3.3 to 2.4

4,877NCT03360539

Nurse-Family Partnership Impact Evaluation in South Carolina

Cervarix/Engerix-B Pooled Group vs Engerix-B Group: Number of Female Subjects With Total Vaccine Effectiveness Against Oropharyngeal Infection With HPV-16/18 Types9 of 3,192

27 of 1,679

-1.3 points

-2.1 to -0.8

4,871NCT00534638

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

Early Intervention vs Late Implementation: Patients Indicated for ACE/ARB and Statin Who Had an Active Prescription for Both1,279 of 2,053

1,318 of 2,803

15.3 points

12.5 to 18.1

4,856NCT02299791

Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics

Counselor vs Provider: Test Offer Rate1,959 of 2,446

861 of 2,409

44.3 points

41.8 to 46.8

4,855NCT00502944

Two Approaches to Routine HIV Testing in a Hospital Emergency Department

Counselor vs Provider: Overall Rapid HIV Testing Rate1,382 of 2,446

643 of 2,409

29.8 points

27.1 to 32.4

4,855NCT00502944

Two Approaches to Routine HIV Testing in a Hospital Emergency Department

Arm A: Continuous Letrozole vs Arm B: Intermittent Letrozole: deaths from any cause170 of 2,426

146 of 2,425

1.0 points

-0.4 to 2.4

4,851NCT00553410

Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer

Intervention vs Control: 30-day COPD Specific, Acute Care Utilization to Any Hospital Within the System179 of 2,353

240 of 2,479

-2.1 points

-3.7 to -0.5

4,832NCT03207776

An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD

Intervention vs Control: Quality, Comfort, and Care (QCC) Defined Readmission Rate286 of 2,353

321 of 2,479

-0.8 points

-2.7 to 1.1

4,832NCT03207776

An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=92

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00991029-7aa4d7cb",
        "title": "Clopidogrel vs Placebo: Myocardial Infarction",
        "summary": "10 of 2432 against 7 of 2449; risk difference 0.1 points, 95% interval -0.2 to 0.5; NCT00991029, Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial",
        "record": "/library/comparisons/NCT00991029-7aa4d7cb",
        "nct_id": "NCT00991029",
        "kind": "outcome",
        "participants": 4881,
        "risk_difference": {
          "value": 0.001253532591175775,
          "lower": -0.0023108328301578804,
          "upper": 0.004996485339499869
        },
        "group_1": "10 of 2,432",
        "group_2": "7 of 2,449",
        "difference": "0.1 points",
        "interval": "-0.2 to 0.5",
        "trial_title": "Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial"
      },
      {
        "id": "NCT00991029-8a641897",
        "title": "Clopidogrel vs Placebo: Minor Hemorrhage",
        "summary": "40 of 2432 against 13 of 2449; risk difference 1.1 points, 95% interval 0.5 to 1.7; NCT00991029, Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial",
        "record": "/library/comparisons/NCT00991029-8a641897",
        "nct_id": "NCT00991029",
        "kind": "outcome",
        "participants": 4881,
        "risk_difference": {
          "value": 0.011139079323461778,
          "lower": 0.005397258683544695,
          "upper": 0.017409714417275447
        },
        "group_1": "40 of 2,432",
        "group_2": "13 of 2,449",
        "difference": "1.1 points",
        "interval": "0.5 to 1.7",
        "trial_title": "Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=93",
  "request_id": "kIYt_n0pK1aKn26b"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?